First clinical data of a natural immunomodulator in colorectal cancer

Ferenc Jakab, Á Mayer, A. Hoffmann, M. Hídvégi

Research output: Article

23 Citations (Scopus)

Abstract

Background/Aims: MSC (trade-name AVEMAR®) is a per os applicable complex of multiple, biologically active molecules obtained from fermented wheat-germ extract. Preclinical studies suggest potent anti-metastatic activity and it has a favorable toxicity profile. It has been aimed in a pilot-scale, phase II clinical study to document whether or not MSC as a support to surgery or plus chemotherapy adds any therapeutic benefit compared to the same combination without MSC in colorectal cancer. Methodology: From 1998 to June 1999, 18 control patients and 12 consecutive colorectal cancer patients respectively, were enrolled into this study. All patients underwent curative surgery. The control group (18 patients) received no other therapy or adjuvant chemotherapy alone. The MSC group (12 patients) received MSC alone or plus adjuvant chemotherapy. Until now, the median follow-up has been 9 months. Results: Interim data of the study document that in the MSC group no new metastases, neither hepatic nor other, have occurred, so far. On the contrary, several new metastases have developed in the control group. Conclusions: Orally administered MSC is a potent candidate to be regarded as a supportive therapy to surgery or plus chemotherapy for colorectal cancer patients.

Original languageEnglish
Pages (from-to)393-395
Number of pages3
JournalHepato-Gastroenterology
Volume47
Issue number32
Publication statusPublished - 2000

Fingerprint

Immunologic Factors
Colorectal Neoplasms
Adjuvant Chemotherapy
Neoplasm Metastasis
Drug Therapy
Control Groups
Names
Therapeutics
Liver

ASJC Scopus subject areas

  • Gastroenterology

Cite this

First clinical data of a natural immunomodulator in colorectal cancer. / Jakab, Ferenc; Mayer, Á; Hoffmann, A.; Hídvégi, M.

In: Hepato-Gastroenterology, Vol. 47, No. 32, 2000, p. 393-395.

Research output: Article

Jakab, F, Mayer, Á, Hoffmann, A & Hídvégi, M 2000, 'First clinical data of a natural immunomodulator in colorectal cancer', Hepato-Gastroenterology, vol. 47, no. 32, pp. 393-395.
Jakab, Ferenc ; Mayer, Á ; Hoffmann, A. ; Hídvégi, M. / First clinical data of a natural immunomodulator in colorectal cancer. In: Hepato-Gastroenterology. 2000 ; Vol. 47, No. 32. pp. 393-395.
@article{60c6eca0fd54454ebf0b20fd5cbe99f4,
title = "First clinical data of a natural immunomodulator in colorectal cancer",
abstract = "Background/Aims: MSC (trade-name AVEMAR{\circledR}) is a per os applicable complex of multiple, biologically active molecules obtained from fermented wheat-germ extract. Preclinical studies suggest potent anti-metastatic activity and it has a favorable toxicity profile. It has been aimed in a pilot-scale, phase II clinical study to document whether or not MSC as a support to surgery or plus chemotherapy adds any therapeutic benefit compared to the same combination without MSC in colorectal cancer. Methodology: From 1998 to June 1999, 18 control patients and 12 consecutive colorectal cancer patients respectively, were enrolled into this study. All patients underwent curative surgery. The control group (18 patients) received no other therapy or adjuvant chemotherapy alone. The MSC group (12 patients) received MSC alone or plus adjuvant chemotherapy. Until now, the median follow-up has been 9 months. Results: Interim data of the study document that in the MSC group no new metastases, neither hepatic nor other, have occurred, so far. On the contrary, several new metastases have developed in the control group. Conclusions: Orally administered MSC is a potent candidate to be regarded as a supportive therapy to surgery or plus chemotherapy for colorectal cancer patients.",
keywords = "Avemar, Colorectal cancer, Combination therapy, Fermented wheat-germ extract, Metastasis, Phase II clinical trial, Pilot study, Supportive therapy",
author = "Ferenc Jakab and {\'A} Mayer and A. Hoffmann and M. H{\'i}dv{\'e}gi",
year = "2000",
language = "English",
volume = "47",
pages = "393--395",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "32",

}

TY - JOUR

T1 - First clinical data of a natural immunomodulator in colorectal cancer

AU - Jakab, Ferenc

AU - Mayer, Á

AU - Hoffmann, A.

AU - Hídvégi, M.

PY - 2000

Y1 - 2000

N2 - Background/Aims: MSC (trade-name AVEMAR®) is a per os applicable complex of multiple, biologically active molecules obtained from fermented wheat-germ extract. Preclinical studies suggest potent anti-metastatic activity and it has a favorable toxicity profile. It has been aimed in a pilot-scale, phase II clinical study to document whether or not MSC as a support to surgery or plus chemotherapy adds any therapeutic benefit compared to the same combination without MSC in colorectal cancer. Methodology: From 1998 to June 1999, 18 control patients and 12 consecutive colorectal cancer patients respectively, were enrolled into this study. All patients underwent curative surgery. The control group (18 patients) received no other therapy or adjuvant chemotherapy alone. The MSC group (12 patients) received MSC alone or plus adjuvant chemotherapy. Until now, the median follow-up has been 9 months. Results: Interim data of the study document that in the MSC group no new metastases, neither hepatic nor other, have occurred, so far. On the contrary, several new metastases have developed in the control group. Conclusions: Orally administered MSC is a potent candidate to be regarded as a supportive therapy to surgery or plus chemotherapy for colorectal cancer patients.

AB - Background/Aims: MSC (trade-name AVEMAR®) is a per os applicable complex of multiple, biologically active molecules obtained from fermented wheat-germ extract. Preclinical studies suggest potent anti-metastatic activity and it has a favorable toxicity profile. It has been aimed in a pilot-scale, phase II clinical study to document whether or not MSC as a support to surgery or plus chemotherapy adds any therapeutic benefit compared to the same combination without MSC in colorectal cancer. Methodology: From 1998 to June 1999, 18 control patients and 12 consecutive colorectal cancer patients respectively, were enrolled into this study. All patients underwent curative surgery. The control group (18 patients) received no other therapy or adjuvant chemotherapy alone. The MSC group (12 patients) received MSC alone or plus adjuvant chemotherapy. Until now, the median follow-up has been 9 months. Results: Interim data of the study document that in the MSC group no new metastases, neither hepatic nor other, have occurred, so far. On the contrary, several new metastases have developed in the control group. Conclusions: Orally administered MSC is a potent candidate to be regarded as a supportive therapy to surgery or plus chemotherapy for colorectal cancer patients.

KW - Avemar

KW - Colorectal cancer

KW - Combination therapy

KW - Fermented wheat-germ extract

KW - Metastasis

KW - Phase II clinical trial

KW - Pilot study

KW - Supportive therapy

UR - http://www.scopus.com/inward/record.url?scp=0034004550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034004550&partnerID=8YFLogxK

M3 - Article

C2 - 10791198

AN - SCOPUS:0034004550

VL - 47

SP - 393

EP - 395

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 32

ER -